摘要
目的比较二线不同化疗方案治疗小细胞肺癌的疗效和安全性。方法按照二线治疗方案不同将84例接受二线方案化疗的小细胞肺癌患者分为伊立替康组38例、依托泊苷组24例和紫杉醇/多西他赛组22例,分别给予伊立替康、依托泊苷、紫杉醇/多西他赛治疗。观察3组患者化疗近期疗效、总生存时间(OS)、无进展生存时间(PFS)以及不良反应发生情况。结果 3组患者DCR、ORR比较,差异无统计学意义(P>0.05);3组患者OS和PFS比较,差异无统计学意义(P>0.05)。伊立替康组Ⅲ~Ⅳ度腹泻发生率明显高于其他2组,差异具有统计学意义(P<0.05);3组患者Ⅲ~Ⅳ度白细胞减少、贫血、血小板减少、乏力、恶心/呕吐、ALT升高、AST升高发生率比较,差异无统计学意义(P>0.05)。结论不同二线化疗方案对一线化疗失败者效果均确切,生存期相近,不良反应除伊立替康组腹泻发生率稍高外,其他Ⅲ~Ⅳ度不良反应发生率均相近。
Objective To explore the clinical effects and security of different therapeutic regimens as second -line treat-ment for small cell lung cancer.Methods 84 cases of patients with small cell lung cancer were divided into irinotecan group （38 cases）,etoposide group（24 cases）,taxol/docetaxel group（22 cases）,they were treated by irinotecan,etoposide,taxol/docetaxel respectively.The clinical effects,OS,PFS,side effects were compared.Results There had no significant difference on the DCR , ORR（P〉0.05）;There had no significant difference in the OS ,PFS（P〉0.05）;The rate ofⅢ~Ⅳdegree diarrhea for the irino-tecan group were higher than the other group （P〈0.05）;There had no significant difference in the rate of Ⅲ~Ⅳ degree hypo-leucocytosis,anemia,thrombopenia,feeble,nausea/vomit,ALT increase,AST increase（P〉0.05）.Conclusion It can lengthen the survival for the patients with small cell lung cancer by different therapeutic regimens as second -line treatment,with similar clinical effects,survival,Ⅲ~Ⅳdegree side effect.
出处
《实用癌症杂志》
2017年第1期61-63,共3页
The Practical Journal of Cancer
关键词
小细胞肺癌
化疗
疗效
安全性
Small cell lung cancer
Chemotherapy
Clinical effects
Security
